Eyelid margin disease (blepharitis and meibomian gland dysfunction): clinical review of evidence-based and emerging treatments

J Cataract Refract Surg. 2024 Aug 1;50(8):876-882. doi: 10.1097/j.jcrs.0000000000001414.

Abstract

Blepharitis is a common ophthalmic condition with multiple etiologies and no definitive, universal treatment. The treatment modalities for managing lid margin diseases vary depending on the disease's cause, location, and severity. For anterior blepharitis, management options include eyelid hygiene with warm compresses, eyelid scrubs, baby shampoo, and over-the-counter eyelid cleansers. Topical antibiotics and antibiotic-steroid combination drops/ointments for the eye and eyelid may accompany these. For posterior blepharitis/meibomian gland dysfunction (MGD), at-home warm compress or in-office administration of heat therapy/thermal pulsation treatment that aims to clear obstruction in the meibomian glands and restore meibum secretions to maintain a healthy tear film is recommended. In addition to the above treatment strategies, various other compounds to manage lid margin diseases are in the late stages of development. This review summarizes the available treatment modalities or those in the pipeline for treating blepharitis and MGD.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Blepharitis* / physiopathology
  • Blepharitis* / therapy
  • Evidence-Based Medicine
  • Humans
  • Meibomian Gland Dysfunction* / physiopathology
  • Meibomian Gland Dysfunction* / therapy
  • Meibomian Glands / physiopathology

Substances

  • Anti-Bacterial Agents